BIOSOLVE-IV Magmaris Swiss Satellite Registry

Inclusion Criteria: * Subject is ≥18 years of age * Subject must be willing to sign a Patient Informed Consent * Symptomatic coronary artery disease * Subject with a maximum of two single de novo lesions in two different major epicardial vessels * Target lesion length ≤ 21 mm by QCA or by visual estimation * Target lesion stenosis \>50% and \<100% by visual estimation, and TIMI flow ≥1. * Subject is eligible for Dual Anti Platelet Therapy (DAPT) * Reference vessel diameter between 2.7-3.7 mm by visual estimation, depending on the scaffold size used Exclusion Criteria: * Pregnant and/or breastfeeding females or females who intend to become pregnant during the time of the registry * Known allergies to: Acetylsalicylic Acid (ASA), clopidogrel, heparin or any other anticoagulant /antiplatelet required for PCI, contrast medium, sirolimus, or similar drugs; or the scaffold materials including Magnesium, Yttrium, Neodymium, Zirconium, Gadolinium, Dysprosium, Tantalum that cannot be adequately pre-medicated * Subjects on dialysis * Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure. Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment * Documented left ventricular ejection fraction (LVEF) ≤30% as documented within maximum 6 months prior to the procedure * Heavily calcified or extremely tortuous lesions * Bifurcation lesion requiring side branch intervention, if side branches \>2 mm in diameter are involved * Restenotic target lesion * Thrombus in target vessel * Target lesion is located in or supplied by a diseased (defined as vessel irregularity per angiogram and \>20% stenosed lesion by visual estimation) arterial or venous bypass graft * Left main coronary artery disease * Ostial target lesion (within 5.0 mm of vessel origin) * Target vessel (including side branches) has second lesion which requires treatment according to the investigator's discretion * Unsuccessful pre-dilatation, defined as residual stenosis rate \>20% by visual estimation and/or angiographic complications (e.g. distal embolization, side branch closure, extensive dissections) * Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained * Currently participating in another study and primary endpoint is not reached yet * Planned interventional treatment of any non-target vessel within 30 days post procedure * Planned intervention of the target vessel within 6-month after the index procedure